Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $2.36, $0.12 better than the analyst estimate of $2.24. Revenue for the quarter came in at $2.45 billion versus the consensus estimate of $2.32 billion.

GUIDANCE:

Quest Diagnostics sees FY2022 EPS of $9.55-$9.95, versus the consensus of $9.33.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.